Diversity of antinuclear antibody responses in hepatocellular carcinoma

Journal of Hepatology

Volumn 26, Issue 6, 1997, Pages 1255-1265

  Covini, Giovanni ^a   Von Mühlen, Carlos A ^a   Pacchetti, Stefania ^a,b   Colombo, Massimo ^a,b   Chan, Edward K L ^a   Tan, Eng M ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Istituto di Medicina Interna   (Italy)

Author keywords

Antinuclear antibody; Autoantibody; Hepatocellular carcinoma

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIGEN; FIBRILLARIN; SMALL NUCLEAR RIBONUCLEOPROTEIN;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ANTIBODY RESPONSE; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS C; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0343471567     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80460-6     Document Type: Article

References (61)

1. Munoz N, Bosch FX. Epidemiology of hepatocellular carcinoma. Okuda K, Ishak KG. Neoplasms of the Liver. 1987;3-19 Springer-Verlag, Tokyo.
2. Whitehouse JM, Holborow EJ. Smooth muscle antibody in malignant disease. Br Med J. 4:1971;511-513.
3. Burnham TK. Antinuclear antibodies in patients with malignancies. Lancet. 2:1972;436.
4. Klein G, Steiner M, Wiener F, Klein E. Human leukemia-associated anti-nuclear reactivity. Proc Natl Acad Sci USA. 71:1974;685-689.
5. Thomas PJ, Kaur JS, Aitcheson CT, Robinson WA, Tan EM. Antinuclear, antinucleolar, and anticytoplasmic antibodies in patients with malignant melanoma. Cancer Res. 43:1983;1372-1380.
6. Hodson ME, Turner-Warwick M. Autoantibodies in patients with bronchial carcinoma. Thorax. 30:1975;367-370.
7. Wasserman J, Glas U, Blomgren H. Autoantibodies in patients with carcinoma of the breast. Correlation with prognosis. Clin Exp Immunol. 19:1975;417-422.
8. Schattner A, Shani A, Talpaz M, Bentwich Z. Rheumatoid factors in the sera of patient with gastrointestinal carcinoma. Cancer. 52:1983;2156-2161.
9. Nelson DS. Autoantibodies in cancer patients. Pathology. 9:1977;155-160.
10. Ablin RJ. Antibodies to lymphocytes in cancer. Lancet. 1:1972;41.
11. Lamelin JP, de-The G, Revillard JP, Gabbiani G. Autoantibodies (cold lymphocytotoxins, antiactin antibodies and antinuclear factors) in nasopharyngeal carcinoma patients. IARC Sci Publ. 1978;523-536.
12. Kostiala AA, Gripenberg M, Elonen E, Gripenberg G, Kostiala I. Follow-up of antibodies against single-stranded DNA in patients with haematological malignancies. Clin Exp Immunol. 61:1985;15-23.
13. Klajman A, Kafri B, Shohat T, Drucker I, Moalem T, Jaretzky A. The prevalence of antibodies to histones induced by procainamide in old people, in cancer patients, and in rheumatoid-like disease. Clin Immunol Immunopathol. 27:1983;1-8.
14. Volkmann M, Muller M, Hofmann WJ, Meyer M, Hagelstein J, Rath U, Kommerell B, Zentgraf H, Galle PR. The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the alpha-fetoprotein status. Hepatology. 18:1993;559-565.
15. Imai H, Ochs RL, Kiyosawa K, Furuta S, Nakamura RM, Tan EM. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol. 140:1992;859-870.
16. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 60:1973;646-649.
17. Barbara L, Benzi G, Gaiani S, Fusconi F, Zironi G, Siringo S, Rigamonti A, Barbara C, Grigioni W, Mazziotti A, Bolondi L. Natural history of small untreated hepatocellular carcinoma in cirrhosis: A multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology. 16:1992;132-137.
18. Ebara M, Ohto M, Shinagawa T, Sugiura N, Kimura K, Matsutani S, Morita M, Saisho H, Tsuchiya Y, Okuda K. Natural history of minute hepatocellular carcinoma smaller than three centimers complicating cirrhosis. Gastroenterology. 90:1986;289-298.
19. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 44:1989;93-151.
20. Fu XD, Maniatis T. Factor required for mammalian spliceosome assembly is localized to discrete regions in the nucleus. Nature. 343:1990;437-441.
21. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
22. Ochs RL, Press RI. Centromere autoantigens are associated with the nucleolus. Exp Cell Res. 200:1992;339-350.
23. Chan EKL, Pollard KM. Autoantibodies to ribonucleoprotein particles by immunoblotting. Rose NR, de Macario EC, Fahey JL, Friedman H, Penn GM. 4th edn. Manual of Clinical Laboratory Immunology. 1992;755-761 American Society for Microbiology, Washington DC.
24. Casiano CA, Landberg G, Ochs RL, Tan EM. Autoantibodies to a novel cell cycle-regulated protein that accumulates in the nuclear matrix during S phase and is localized in the kinetochores and spindle midzone during mitosis. J Cell Sci. 106:1993;1045-1056.
25. Chan EKL, Tan EM. Human autoantibody-reactive epitopes of SS-B/La are highly conserved in comparison with epitopes recognized by murine monoclonal antibodies. J Exp Med. 166:1987;1627-1640.
26. Olmsted JB. Affinity purification of antibodies from diazotized paper blots of heterogeneous protein samples. J Biol Chem. 256:1981;11955-11957.
27. Rattner JB, Rao A, Fritzler MJ, Valencia DW, Yen TJ. CENP-F is a ca. 400 kDa kinetochore protein that exhibits a cell-cycle dependent localization. Cell Motil Cytoskeletron. 26:1993;214-226.
28. Tan EM. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol. 33:1982;167-240.
29. Hillyer GV. Deoxyribonucleic acid (DNA) and antibodies to DNA in the serum of hamsters and man infected with schistosomes. Proc Soc Exp Biol Med. 136:1971;880-883.
30. Lindsley HB, Kysela S, Steinberg AD. Nucleic acid antibodies in African trypanosomiasis: studies in Rhesus monkeys and man. J Immunol. 113:1974;1921-1927.
31. Pedersen JS, Toh BH, Locarnini SA, Gust ID, Shyamala GN. Autoantibody to intermediate filaments in viral hepatitis. Clin Immunol Immunopathol. 21:1981;154-161.
32. Toh BH, Yildiz A, Sotelo J, Osung O, Holborow EJ, Kanakoudi F, Small JV. Viral infections and IgM autoantibodies to cytoplasmic intermediate filaments. Clin Exp Immunol. 37:1979;76-82.
33. Toh H, Hayashida H, Miyata T. Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus. Nature. 305:1983;827-829.
34. Fusconi M, Lenzi M, Ballardini G, Miniero R, Cassani F, Zauli D, Bianchi FB. Anti-HCV testing in autoimmuno hepatitis and primary biliary cirrhosis. Lancet. 33:1993;823.
35. Lunel F, Abuaf N, Frangeul L, Grippon P, Perrin M, Le Co Y, Valla D, Borotto E, Yamamoto AM, Huraux JM, et al. Liver/kidney microsome antibody type 1 and hepatitis virus infection. Hepatology. 16:1992;630-636.
36. Lenzi M, Ballardini G, Fusconi M, Cassani F, Selleri L, Volt U, Zauli D, Bianchi FB. Type 2 autoimmune hepatitis and hepatitis C virus infection. Lancet. 335:1990;258-259.
37. Lenzi M, Johnson PJ, McFarlane IG, Ballardini G, Smith HM, McFarlane BM, Bridger C, Vergani D, Bianchi FB, Williams R. Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity. Lancet. 338:1991;277-280.
38. Fiorini G, Bernasconi P, Sinico RA, Chianese R, Pozzi D'Amico G. Increased frequency of antibodies to ubiquitoun viruses in essential mixed cryoglobulinaemia. Clin Exp Immunol. 64:1986;65-70.
39. Mishiro S, Takeda K, Hoshi Y, Yoshikawa A, Gotanda, Itoh Y. An autoantibody cross-reactive to hepatitis C virus core and a host nuclear antigen. Autoimmunity. 16:1991;269-273.
40. Tran A, Quaranta JF, Benzaken S, Thiers V, Chau HT, Hasier P, Regnier D, Dreyfus G, Pradier C, Sadoul JL, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology. 18:1993;253-257.
41. Preziati D, La Rosa L, Covini G, Marcelli R, Rescalli S, Pessani L, Del Ninno E, Meroni PL, Colombo M, Beck-Pecco P. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol. 132:1995;587-593.
42. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM autoantibodies recognize a short linear sequence P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest. 88:1991;1370-1378.
43. Okamoto H, Tsuda F, Machida A, Munekata E, Akahane Y, Sugai Y, Mashiko K, Mitsui T, Tanaka T, Miyakawa Y, et al. Antibodies against synthetic oligopeptides deduced from the putative core gene for the diagnosis of hepatitis virus infection. Hepatology. 15:1992;180-186.
44. Hosein B, Fang X, Wang CY. Anti-HCV, anti-GOR, and autoimmunity. Lancet. 339:1992;871.
45. Tan EM. Autoantibodies in pathology and cell biology. Cell. 67:1991;841-842.
46. Popper H, Sternberg SS, Oser BC, Oser M. The carcinogen effect of aramite in rats. A study of hepatic nodules. Cancer. 13:1960;1035-1046.
47. Solt DB, Medline A, Farber E. Rapid emergence of carcinogen-induced hyperplastic lesions in a new model for the sequential analysis of liver carcinogenesis. Am J Pathol. 88:1977;595-618.
48. Farber E. Cellular biochemistry of the stepwise development of cancer with chemicals: G. H. A. Clowes memorial lecture. Cancer Res. 44:1984;5463-5474.
49. Bannasch P, Keppler D, Weber G. The biochemical-molecular pathology of the stepwise development of liver cancer: new insights and problems. 51st edn. Anonymous Liver Cell Carcinoma. 1989;273-291 Kluwer Academic Publishers, Dordrecht. Falk Symposium.
50. Imai H, Chan EKL, Kiyosawa K, Fu XD, Tan Em. Now nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. J Clin Invest. 92:1993;2419-2426.
51. Eliceiri GL, Ryerse JS. Detection of intranuclear clusters of Sm antigens with monoclonal anti-Sm antibodies by immunoelectron microscopy. J Cell Physiol. 121:1984;449-451.
52. Spector DL. Macromolecular domains within the cell nucleus. Annu Rev Cell Biol. 9:1993;265-315.
53. Kass S, Tyc K, Steitz JA, Sollner-Webb B. The U3 small nucleolar ribonucleoprotein functions in the first step of preribosomal RNA processing. Cell. 60:1990;897-908.
54. Hirakata M, Mimori T, Akizuki M, Craft J, Hardin JA, Homma M. Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inflammatory muscle disease. Arthritis Rheum. 35:1992;449-456.
55. Earnshaw WC, Mackay AM. Role of nonhistone proteins in the chromosomal events of mitosis. FASEB J. 8:1994;947-956.
56. Casiano CA, Humbel RL, Peebles C, Covini G, Tan EM. Autoimmunity to the cell cycle-dependent centromere protein p330d/CENP-F in disorders associated with cell proliferation. J Autoimmun. 8:1995;575-586.
57. Lewis MG, Ikonopisov RL, Nairn RC, Phillips TM, Fairley GH, Bodenham DC, Alexander P. Tumour-specific antibodies in human malignant melanoma and their relationship to the extent of the disease. Br Med J. 3:1969;547-552.
58. Lewis MG, Avis PJ, Phillips TM, Sheikh KM. Tumor-associated antigens in human malignant melanoma. Yale J Biol Med. 46:1973;661-668.
59. McBride CM, Bowen JM, Dmochowski LL. Antinucleolar antibodies in the sera of patients with malignant melanoma. Surg Forum. 23:1972;92-93.
60. Turnbull AR, Turner DT, Fraser JD, Lloyd RS, Lang CJ, Wright R. Autoantibodies in early breast cancer: a stage-related phenomenon? Br J Cancer. 38:1978;461-463.
61. Okuda K, Obata H, Nakajima Y, Ohtsuki T, Okazaki N, Ohnishi K. Prognosis of primary hepatocellular carcinoma. Hepatology. 4:1984;3S-6S.